Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, Korea.
Ann Lab Med. 2021 Sep 1;41(5):455-462. doi: 10.3343/alm.2021.41.5.455.
The prevalence of extended-spectrum β-lactamase-producing (ESBL-EC) in the community has increased worldwide due to multifactorial reasons. ESBL-EC bloodstream infection (BSI) complicates the decision for proper antimicrobial administration. In this multicenter study, we investigated the prevalence, risk factors, and molecular background of community-onset (CO) ESBL-EC BSI.
We included data for all episodes of ESBL-EC BSI of community origin from May 2016 to April 2017 obtained from the Korean national antimicrobial resistance surveillance system, which comprises six sentinel hospitals. Data, including previous history of admission and use of antimicrobials and medical devices before BSI, were collected, along with microbiological analysis results.
Among 1,189 patients with CO BSI caused by , 316 (27%) were identified as ESBL producers. History of admission, especially to a long-term care hospital (LTCH), and previous use of β-lactams/β-lactamase inhibitors, carbapenem, lincosamide, aminoglycoside, and extended-spectrum cephalosporin were independent risk factors for CO ESBL-EC BSI; admission to an LTCH showed the highest odds ratio (3.8, 95% confidence interval 2.3-6.1). The most common genotype was CTX-M-15 (N=131, 41%), followed by CTX-M-14 (N=86, 27%). ST131 was the most common sequence type among ESBL-EC groups (57%).
In Korea, 27% of CO BSI were caused by ESBL producers. From perspectives of empirical treatment and infection control, history of admission to an LTCH and antimicrobial use should be noted.
由于多种因素,社区中产超广谱β-内酰胺酶(ESBL)的流行率在全球范围内有所增加。产 ESBL 肠杆菌科细菌血流感染(BSI)使适当抗菌药物管理的决策复杂化。在这项多中心研究中,我们调查了社区获得性(CO)产 ESBL 肠杆菌科细菌 BSI 的流行率、危险因素和分子背景。
我们纳入了 2016 年 5 月至 2017 年 4 月从韩国国家抗菌药物耐药性监测系统(包括六家监测医院)获得的所有社区起源的 ESBL-EC BSI 病例的数据。收集了包括 BSI 前入院和使用抗菌药物和医疗器械的既往史,以及微生物分析结果。
在 1189 例社区获得性 ESBL-EC BSI 患者中,316 例(27%)被鉴定为 ESBL 产生者。入院史,尤其是长期护理医院(LTCH)入院史,以及β-内酰胺/β-内酰胺酶抑制剂、碳青霉烯类、林可酰胺类、氨基糖苷类和扩展谱头孢菌素类的既往使用是 CO ESBL-EC BSI 的独立危险因素;入住 LTCH 的患者具有最高的比值比(3.8,95%置信区间 2.3-6.1)。最常见的基因型是 CTX-M-15(N=131,41%),其次是 CTX-M-14(N=86,27%)。ESBL-EC 组中最常见的序列类型是 ST131(57%)。
在韩国,27%的 CO BSI 是由 ESBL 产生者引起的。从经验性治疗和感染控制的角度来看,应注意 LTCH 入院史和抗菌药物使用情况。